[1] Glenthøj A, Ørskov AD, Hansen JW, et al. Immune Mechanisms in Myelodysplastic Syndrome[J]. Int J Mol Sci,2016,17(6),pii:E944. [2] Gañán-Gómez I, Wei Y, Starczynowski DT, et al.Deregu-lation of innate immune and inflammatory signaling in myelodysplastic syndromes[J]. Leukemia,2015,29(7):1458-1469. [3] 李晓, 应韶旭, 刘薏芝, 等. 骨髓增生异常综合征巨噬细胞增生与造血细胞凋亡的相关性[J]. 中华病理学杂志,2003,32(3):226-229. [4] Kitagawa M, Kamiyama R, Kasuga T.Increase in number of bone marrow macrophages in patients with myelodysplastic syndromes[J]. Eur J Haematol,1993,51(1):56-58. [5] 吴凌云, 李晓, 常春康, 等. 骨髓增生异常综合征患者T细胞异常极化导致的负性造血调控[J]. 中华血液学杂志,2007,28(8):549-554. [6] Allavena P, Sica A, Garlanda C, et al.The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance[J]. Immunol Rev,2008,222:155-161. [7] Mantovani A, Sozzani S, Locati M, et al.Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes[J]. Trends Immunol,2002,23(11):549-555. [8] Komohara Y, Hasita H, Ohnishi K, et al.Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma[J]. Cancer Sci,2011,102(7):1424-1431. [9] Kamper P, Bendix K, Hamilton-Dutoit S, et al.Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma[J]. Haematologica,2011,96(2):269-276. [10] Itoh M, Yago K, Shimada H, et al.Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome[J]. Int J Hematol,2002,75(3):302-304. [11] Ohmori S, Ohmori M, Yamagishi M, et al.MDS-macrophage derived inhibitory activity on myelopoiesis of MDS abnormal clones[J]. Br J Haematol,1993,83(3):388-391. [12] Hom J, Dulmovits BM, Mohandas N, et al.The erythroblastic island as an emerging paradigm in the anemia of inflammation[J]. Immunol Res,2015,63(1-3):75-89. [13] Reza S, Dar S, Andric T, et al.Biologic characteristics of 164 patients with myelodysplastic syndromes[J]. Leuk Lymphoma,1999,33(3-4):281-287. [14] Motomura S, Motoji T, Okutomi K, et al.Successful treatment of refractory anemia by high-dose methylprednisolone associated with an increment in CD68-positive cells in bone marrow[J]. Am J Hematol,2001,66(2):80-84. |